
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/25162/publications.pdf Version: 2024-02-01



TODOD DODOV

#	Article	IF	CITATIONS
1	Development and validation of the food allergy severity score. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1545-1558.	5.7	19
2	Time course of disease characteristics in patients with severe allergic asthma starting treatment with omalizumab. Annals of Allergy, Asthma and Immunology, 2022, , .	1.0	0
3	Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study. BioMed Research International, 2022, 2022, 1-7.	1.9	2
4	The roadmap for allergology in Europe: The European training requirements for the specialty of allergology. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1588-1591.	5.7	4
5	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	2.4	6
6	Medical devices in allergy practice. World Allergy Organization Journal, 2020, 13, 100466.	3.5	7
7	Fractional exhaled breath temperature in patients with asthma, chronic obstructive pulmonary disease, or systemic sclerosis compared to healthy controls. European Clinical Respiratory Journal, 2020, 7, 1747014.	1.5	9
8	International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants. World Allergy Organization Journal, 2020, 13, 100106.	3.5	94
9	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	5.7	29
10	<p>In vitro and in vivo Evaluation of the Efficacy and Safety of Powder Hydroxypropylmethylcellulose as Nasal Mucosal Barrier</p> . Medical Devices: Evidence and Research, 2020, Volume 13, 107-113.	0.8	6
11	Inâ€vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2161-2169.	5.7	23
12	Food Allergy in Adults: Substantial Variation in Prevalence and Causative Foods Across Europe. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1920-1928.e11.	3.8	109
13	In-Vitro Setup to Test Hydroxy-Propyl-Methyl-Cellulose as Allergen Barrier over a Span of 360 Minutes. Journal of Allergy and Clinical Immunology, 2019, 143, AB193.	2.9	1
14	Powder Cellulose in Allergic Rhinitis Management: Relevance of in vitro Findings to Real-Life Safety. International Archives of Allergy and Immunology, 2019, 179, 17-18.	2.1	2
15	In vitro study of the adsorption of 2.5 μm particles (PM2.5) by hydroxy-propyl-methyl-cellulose powder (HPMC). Journal of Allergy and Clinical Immunology, 2019, 143, AB24.	2.9	1
16	Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. World Allergy Organization Journal, 2019, 12, 100079.	3.5	2
17	<scp>ARIA</scp> pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy― Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
18	The roadmap for allergology in Europe: The subspecialty of allergology as "stopâ€over―on the way to a full specialty. An <scp>EAACI</scp> position statement. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 540-548.	5.7	20

#	Article	IF	CITATIONS
19	Componentâ€resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 549-559.	5.7	60
20	Current practice of allergy diagnosis and the potential impact of regulation in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 323-327.	5.7	17
21	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Journal of Pragmatic and Observational Research, 2018, Volume 9, 29-42.	1.5	18
22	Benefits of Nasal Cellulose Powder Application Depend on the Type of Allergen Sensitization in Allergic Rhinitis. Allergy, Asthma and Immunology Research, 2018, 10, 182.	2.9	0
23	The added value of exhaled breath temperature in respiratory medicine. Journal of Breath Research, 2017, 11, 034001.	3.0	20
24	A Double Blind Placebo Controlled Study Documenting the Effect of Nasally Applied Cellulose-Derived Powder in Subjects Sensitized to Grass Pollen. Journal of Allergy and Clinical Immunology, 2017, 139, AB386.	2.9	1
25	Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1015-1024.e8.	3.8	82
26	Methyl-cellulose powder for prevention and management of nasal symptoms. Expert Review of Respiratory Medicine, 2017, 11, 885-892.	2.5	24
27	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	6.7	64
28	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47
29	The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma. Pulmonary Pharmacology and Therapeutics, 2016, 39, 54-63.	2.6	100
30	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
31	Real-Life Study on the Effect of Micronized Cellulose Powder As Add-on to Intranasal As-Needed Treatment of Subjects with Pollen Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 2016, 137, AB402.	2.9	4
32	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
33	Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma. Data in Brief, 2016, 9, 199-205.	1.0	1
34	Relationship Between Exhaled Breath Temperature and Ear Temperature in Otherwise Healthy Persons during Febrile Infectious Illness. Journal of Allergy and Clinical Immunology, 2016, 137, AB202.	2.9	1
35	Exhaled breath temperature measurement: Applicability in childhood. Pediatric Pulmonology, 2016, 51, 91-92.	2.0	2
36	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47

TODOR POPOV

#	Article	IF	CITATIONS
37	Clinical characteristics of patients seeking medical advice for nasal symptoms in Bulgaria with special focus on children. World Allergy Organization Journal, 2016, 9, 11.	3.5	1
38	Budesonide/salmeterol in fixed-dose combination for the treatment of asthma. Expert Review of Respiratory Medicine, 2016, 10, 113-125.	2.5	2
39	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
40	A Single Breath Method to Assess the Relative Contribution of Central and Peripheral Airways to Overall Exhaled Breath Temperature. Journal of Allergy and Clinical Immunology, 2015, 135, AB177.	2.9	1
41	Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. Allergy and Asthma Proceedings, 2015, 36, 134-139.	2.2	14
42	Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. World Allergy Organization Journal, 2015, 8, 25.	3.5	328
43	Hazelnut allergy across Europe dissected molecularly: AÂEuroPrevall outpatient clinic survey. Journal of Allergy and Clinical Immunology, 2015, 136, 382-391.	2.9	92
44	Integrating Evidence for Managing Asthma in Patients Who Smoke. Allergy, Asthma and Immunology Research, 2014, 6, 114.	2.9	22
45	Frequent cough in unsatisfactory controlled asthma – results from the population-based West Sweden Asthma Study. Respiratory Research, 2014, 15, 79.	3.6	31
46	Biologic agents and the therapy of chronic spontaneous urticaria. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 347-353.	2.3	9
47	Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2014, 113, 108-113.	1.0	4
48	A real $\hat{a} \in$ life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough. Cough, 2014, 10, 2.	2.7	14
49	Nightâ€time sedating H ₁ â€antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. British Journal of Dermatology, 2014, 171, 148-154.	1.5	58
50	Exhaled breath temperature: broadening the horizons [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 250-251.	1.2	4
51	Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways ofÂasthmatics. Pulmonary Pharmacology and Therapeutics, 2013, 26, 624-629.	2.6	28
52	Effect of montelukast for treatment of asthma in cigarette smokers. Journal of Allergy and Clinical Immunology, 2013, 131, 763-771.e6.	2.9	58
53	Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens. Journal of Allergy and Clinical Immunology, 2013, 131, 164-171.	2.9	82
54	What we should learn from the London Olympics. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 1-3.	2.3	9

#	Article	IF	CITATIONS
55	Characteristics of a patient population seeking medical advice for nasal symptoms in Bulgaria. Annals of Allergy, Asthma and Immunology, 2012, 108, 232-236.	1.0	6
56	Maintenance of Skills, Competencies, and Performance in Allergy and Clinical Immunology: Time to Lay the Foundation for a Universal Approach. World Allergy Organization Journal, 2012, 5, 45-51.	3.5	3
57	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
58	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA ² LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	2.1	83
59	Human exhaled breath analysis. Annals of Allergy, Asthma and Immunology, 2011, 106, 451-456.	1.0	161
60	Challenges in the Management of Chronic Urticaria. World Allergy Organization Journal, 2011, 4, S28-S31.	3.5	3
61	Challenges in the Management of Chronic Urticaria. World Allergy Organization Journal, 2011, 4, S28-S31.	3.5	6
62	Pooled analysis of studies on DNA adducts and dietary vitamins. Mutation Research - Reviews in Mutation Research, 2010, 705, 77-82.	5.5	13
63	Development and implementation of guidelines in allergic rhinitis – an ARIAâ€GA ² LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	5.7	85
64	Temperatura do ar exalado, um novo biomarcador no controle da asma: um estudo piloto. Jornal Brasileiro De Pneumologia, 2010, 36, 693-699.	0.7	28
65	Daily Monitoring of Asthmatics by Means of Individual Devices for Exhaled Breath Temperature Measurement. IEEE Sensors Journal, 2010, 10, 44-48.	4.7	11
66	The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Journal of Allergy and Clinical Immunology, 2010, 125, 676-682.	2.9	278
67	Development of an Individual Device for Exhaled Breath Temperature Measurement. IEEE Sensors Journal, 2010, 10, 110-113.	4.7	16
68	Exhaled Breath Temperature Measurement Made Easy. Pediatric Allergy and Immunology, 2009, 20, 200-201.	2.6	13
69	Effect of vitamin levels on biomarkers of exposure and oxidative damage—The EXPAH study. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 672, 129-134.	1.7	21
70	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 8-160.	5.7	3,827
71	The association of pet keeping at home with symptoms in airways, nose and skin among Bulgarian children. Pediatric Allergy and Immunology, 2008, 19, 702-708.	2.6	42
72	Genetic Susceptibility to Benzene Toxicity in Humans. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2008, 71, 1482-1489.	2.3	21

TODOR POPOV

#	Article	IF	CITATIONS
73	Circadian Changes in the Sputum of Asthmatic Subjects and Healthy Controls. World Allergy Organization Journal, 2008, 1, 74-78.	3.5	6
74	Evaluation of a simple, potentially individual device for exhaled breath temperature measurement. Respiratory Medicine, 2007, 101, 2044-2050.	2.9	76
75	Role ofGSTT1 deletion in DNA oxidative damage by exposure to polycyclic aromatic hydrocarbons in humans. International Journal of Cancer, 2007, 120, 2499-2503.	5.1	30
76	Effects of polycyclic aromatic hydrocarbons (PAHs) in environmental pollution on exogenous and oxidative DNA damage (EXPAH project): Description of the population under study. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 1-6.	1.0	46
77	Effects of metabolic genotypes on intermediary biomarkers in subjects exposed to PAHS: Results from the EXPAH study. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 7-15.	1.0	18
78	Biomarkers of exposure to carcinogenic PAHs and their relationship with environmental factors. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 16-21.	1.0	34
79	Influence of PAHs in ambient air on chromosomal aberrations in exposed subjects: International study – EXPAH. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 41-48.	1.0	5
80	Chromosomal aberrations by fluorescence in situ hybridization (FISH)—Biomarker of exposure to carcinogenic PAHs. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 62-70.	1.0	13
81	Effects of environmental air pollution on endogenous oxidative DNA damage in humans. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 71-82.	1.0	53
82	The relationship between biomarkers of oxidative DNA damage, polycyclic aromatic hydrocarbon DNA adducts, antioxidant status and genetic susceptibility following exposure to environmental air pollution in humans. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 83-92.	1.0	109
83	Sensitivity of different endpoints for in vitro measurement of genotoxicity of extractable organic matter associated with ambient airborne particles (PM10). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 103-113.	1.0	16
84	Exposure to environmental polycyclic aromatic hydrocarbons: Influences on cellular susceptibility to DNA damage (sampling KoÅjice and Sofia). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 620, 145-154.	1.0	23
85	A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflammation Research, 2006, 55, 241-244.	4.0	41
86	The use of S-phenylmercapturic acid as a biomarker in molecular epidemiology studies of benzene. Chemico-Biological Interactions, 2005, 153-154, 97-102.	4.0	28
87	Biomarkers of exposure and effect in Bulgarian petrochemical workers exposed to benzene. Chemico-Biological Interactions, 2005, 153-154, 247-251.	4.0	13
88	Specific immune responses in workers exposed to benzene. International Immunopharmacology, 2005, 5, 1554-1559.	3.8	11
89	Molecular epidemiology studies of carcinogenic environmental pollutants. Mutation Research - Reviews in Mutation Research, 2003, 544, 397-402.	5.5	165
90	Cytogenetic effects of hexavalent chromium in Bulgarian chromium platers. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 514, 29-38.	1.7	71

#	Article	IF	CITATIONS
91	Possibilities to control the health risk of petrochemical workers. International Archives of Occupational and Environmental Health, 2002, 75, 21-26.	2.3	32
92	Assessment of the correlation between exposure to benzene and urinary excretion of t , t -muconic acid in workers from a petrochemical plant. International Archives of Occupational and Environmental Health, 2002, 75, 97-100.	2.3	18
93	Comparison of the clinical efficacy of standard and mucoadhesive-based nasal decongestants. British Journal of Clinical Pharmacology, 2002, 53, 107-109.	2.4	8
94	Monitoring of fluctuating airway obstruction and episodes of coughing by thoracic electrical impedance. Journal of Medical Engineering and Technology, 2001, 25, 49-52.	1.4	1
95	Occupational exposure to Cr(VI): comparison between chromium levels in lymphocytes, erythrocytes, and urine. International Archives of Occupational and Environmental Health, 1996, 69, 39-44.	2.3	31
96	DNA-protein crosslinks in peripheral lymphocytes of individuals exposed to hexavalent chromium compounds. Biomarkers, 1996, 1, 86-93.	1.9	41
97	Spontaneous and induced sputum to measure indices of airway inflammation in asthma American Journal of Respiratory and Critical Care Medicine, 1996, 154, 866-869.	5.6	212
98	Some technical factors influencing the induction of sputum for cell analysis. European Respiratory Journal, 1995, 8, 559-65.	6.7	84